New antibody-based Nano kit enables fast detection of H. pylori

Early detection of infections caused by Helicobacter pylori (H. pylori) is considered one of the most effective strategies for preventing gastric ulcers and reducing the risk of gastric cancer. In this context, an Iranian knowledge-based company has successfully developed a rapid nano-diagnostic kit that can accurately identify the presence of the bacterium in human samples without the need for invasive procedures.

The product, developed using Lateral Flow Assay (LFA) technology, enables rapid, simple, and affordable detection of H. pylori infections in healthcare facilities, diagnostic laboratories, and even home settings. Experts believe that broader access to such diagnostic tools could significantly enhance screening programs, facilitate early diagnosis, and reduce the burden of gastrointestinal diseases, particularly in developing countries.

As gastrointestinal disorders continue to pose major public health challenges worldwide, the development of rapid and accurate diagnostic technologies is expected to play a crucial role in disease control and prevention. The newly developed nano-based diagnostic kit specifically targets H. pylori, one of the most widespread infectious agents globally.

According to international estimates, more than half of the world's population encounter H. pylori during their lifetime. The global prevalence of the infection is estimated at approximately 44 percent, and health experts regard the bacterium as one of the leading risk factors for chronic gastric diseases and several gastrointestinal cancers.

The diagnostic kit employs antibody-based rapid detection technology and is designed to identify H. pylori surface antigens in stool samples. Compared with many conventional diagnostic methods, the technology offers several advantages, including faster results, lower costs, elimination of the need for sophisticated laboratory equipment, and a completely non-invasive testing process.

A key feature of the product is its applicability across a wide range of healthcare and diagnostic environments. Medical laboratories, healthcare centers, hospitals, gastroenterology clinics, pharmacies, and even individual users can utilize the kit for screening and preliminary diagnosis. This flexibility is expected to improve access to diagnostic services and streamline patient identification processes.

In addition to this product, the company is actively engaged in the development and production of various rapid diagnostic kits based on Lateral Flow Assay technology. Such technologies provide fast, user-friendly, and cost-effective diagnostic solutions, particularly in emergency situations, underserved regions, and healthcare facilities with limited access to advanced laboratory infrastructure.

The company stated that all of its products are manufactured and marketed in compliance with international quality management and medical device standards.

Experts note that domestic development of such technologies can not only reduce dependence on imported products, but also strengthen national screening systems, improve patient access to diagnostic services, and lower overall healthcare expenditures.